title: Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter study.
abstract: OBJECTIVE
  To evaluate the usefulness of 2-[18F]-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in IgG4-related disease (IgG4-RD) for the staging of the disease and the followup under treatment.
  
  
  METHODS
  All patients included in the French IgG4-RD registry who underwent ≥1 FDG-PET/CT scan were included in the study. Clinical, biologic, pathologic, radiologic, and FDG-PET/CT qualitative and quantitative findings were retrospectively collected and analyzed.
  
  
  RESULTS
  Twenty-one patients were included in the study and 46 FDG-PET/CT examinations were evaluated. At either diagnosis or relapse, all evaluated patients presented abnormal 18F-FDG uptake in typical IgG4-RD localizations. In most cases, FDG-PET/CT was more sensitive than conventional imaging to detect organ involvement, especially in arteries, salivary glands, and lymph nodes. In few cases (small-sized lesions and brain or kidney contiguous lesions), false-negative results were noted. Evaluation before and after treatment showed in most cases a good correlation of FDG-PET/CT results with treatment response and disease activity.
  
  
  CONCLUSIONS
  This large retrospective study shows that FDG-PET/CT imaging is useful for the staging of IgG4-RD. Moreover, FDG-PET/CT is useful to assess the response to treatment during followup.
authors.affiliation: Centre Hospitalier Universitaire de la Conception, AP-HM, Aix-Marseille Université, Marseille, France.
authors.forename: Mikael
authors.initials: M
authors.lastname: Ebbo
authors.forename: Aurélie
authors.initials: A
authors.lastname: Grados
authors.forename: Eric
authors.initials: E
authors.lastname: Guedj
authors.forename: Delphine
authors.initials: D
authors.lastname: Gobert
authors.forename: Cécile
authors.initials: C
authors.lastname: Colavolpe
authors.forename: Mohamad
authors.initials: M
authors.lastname: Zaidan
authors.forename: Agathe
authors.initials: A
authors.lastname: Masseau
authors.forename: Fanny
authors.initials: F
authors.lastname: Bernard
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Berthelot
authors.forename: Nathalie
authors.initials: N
authors.lastname: Morel
authors.forename: François
authors.initials: F
authors.lastname: Lifermann
authors.forename: Sylvain
authors.initials: S
authors.lastname: Palat
authors.forename: Julien
authors.initials: J
authors.lastname: Haroche
authors.forename: Xavier
authors.initials: X
authors.lastname: Mariette
authors.forename: Bertrand
authors.initials: B
authors.lastname: Godeau
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Bernit
authors.forename: Nathalie
authors.initials: N
authors.lastname: Costedoat-Chalumeau
authors.forename: Thomas
authors.initials: T
authors.lastname: Papo
authors.forename: Mohamed
authors.initials: M
authors.lastname: Hamidou
authors.forename: Jean-Robert
authors.initials: JR
authors.lastname: Harlé
authors.forename: Nicolas
authors.initials: N
authors.lastname: Schleinitz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000175:diagnosis* / Q000188:drug therapy* / Q000378:metabolism; D049268:Positron-Emission Tomography / Q000379:methods*; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D000069283:Rituximab; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D013256:Steroids / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D013256:Steroids; D019788:Fluorodeoxyglucose F18; D000069283:Rituximab; D011241:Prednisone